Vaping-associated mechanisms in the development of gastroesophageal reflux disease

Abstract

BACKGROUND: There is compelling evidence of the negative impact of vaping on the respiratory and cardiovascular systems. However, its effects on the gastrointestinal tract remain understudied.

AIM: The study aimed to assess the impact of vaping on the functional state of the gastroesophageal zone in healthy individuals compared with patients with gastroesophageal reflux disease (GERD).

METHODS: The study included 90 participants divided into three groups of 30 individuals each. Group 1 consisted of individuals with no gastrointestinal disorders who had been regularly vaping for more than 12 months. Group 2 included patients with GERD. Group 3 (control group) comprised healthy individuals with no harmful habits. Clinical manifestations of reflux syndrome were assessed using validated questionnaires. Participants underwent 24-hour impedance-pH monitoring, and serum levels of gastrin and motilin were measured. Statistical analysis was performed using the Kruskal–Wallis test and Dunn test. Fisher exact test was used for comparing qualitative variables, whereas Spearman correlation coefficient was applied for dependency assessment. The significance threshold was set at p < 0.05.

RESULTS: In Group 2 (GERD), a low pH level in the lower esophagus and a high daily frequency of all types of reflux episodes were recorded. Compared with the control group, patients in group 2 had lower serum motilin levels (83.2 [56.9; 99.3] pg/mL vs 189.7 [117.6; 362.3] pg/mL, p = 0.001). Vapers had a more pronounced reflux syndrome compared with healthy individuals, with an increased daily number of acidic (54 [39.5; 71] vs 21.5 [18; 28.8], p = 0.001) and weakly acidic (7.5 [4.3; 9.8] vs 2 [1; 3], p = 0.001) reflux episodes, along with a decrease in esophageal pH levels (4.7 [4.1; 5.9] vs 6.7 [6.2; 6.8], p = 0.001).

CONCLUSION: Vaping is associated with an increased number of gastroesophageal reflux episodes, likely due to the suppression of lower esophageal sphincter motility, and may contribute to the development of GERD.

Keywords

vaping / 24-hour impedance-pH monitoring / motilin / gastrin

References

[1] Podzolkov VI, Vetluzhskaya MV, Abramova AA, et al. Vaping and vaping-associated lung injury: A review. Terapevticheskii Arkhiv. 2023;95(7):591–596. doi: 10.26442/00403660.2023.07.202293

[2] Подзолков В.И., Ветлужская М.В., Абрамова А.А., и др. Вейпинг и вейп-ассоцированное поражение легких // Терапевтический архив. 2023. Т. 95, № 7. С. 591–596. doi: 10.26442/00403660.2023.07.202293

[3] Makarova IA, Akatova EV, Nikolin OP, Ivanova OS. Vaping is a bad habit or subculture. Narcology. 2024;23(2):60–78. doi: 10.25557/1682-313.2024.02.60-78

[4] Макарова И.А., Акатова Е.В., Николин О.П., Иванова О.С. Вейпинг – вредная привычка или субкультура // Наркология. 2024. Т. 23, № 2. С. 60–78. doi: 10.25557/1682-8313.2024.02.60-78

[5] David A Savitz. Invited commentary: the epidemiology of electronic cigarettes and reproductive health begins. Am J Epidemiol. 2021;190(3):362–364. doi: 10.1093/aje/kwaa066

[6] Savitz DA. Invited commentary: the epidemiology of electronic cigarettes and reproductive health begins // Am J Epidemiol. 2021. Vol. 190, N. 3. P. 362–364. doi: 10.1093/aje/kwaa066

[7] Li X, Yuan L, Wang F. Health outcomes of electronic cigarettes. Chin Med J. 2024;137(16):1903–1911. doi: 10.1097/CM9.0000000000003098

[8] Li X., Yuan L., Wang F. Health outcomes of electronic cigarettes // Chin Med J. 2024. Vol. 137, N. 16. P. 1903–1911. doi: 10.1097/CM9.0000000000003098

[9] Skotsimara G, Antonopoulos AS, Oikonomou E, et al. Cardiovascular effects of electronic cigarettes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2019;26(11):219–1228. doi: 10.1177/2047487319832975

[10] Skotsimara G., Antonopoulos A.S., Oikonomou E., et al. Cardiovascular effects of electronic cigarettes: A systematic review and meta-analysis // Eur J Prev Cardiol. 2019. Vol. 26, N. 11. P. 1219–1228. doi: 10.1177/2047487319832975

[11] Lyzwinski LN, Naslund JA, Miller CJ, Eisenberg MJ. Global youth vaping and respiratory health: epidemiology, interventions, and policies. NPJ Prim Care Respir Med. 2022;32(1):14. doi: 10.1038/s41533-022-00277-9

[12] Lyzwinski L.N., Naslund J.A., Miller C.J., Eisenberg M.J. Global youth vaping and respiratory health: epidemiology, interventions, and policies // NPJ Prim Care Respir Med. 2022. Vol. 32, N. 1. P. 14. doi: 10.1038/s41533-022-00277-9

[13] Pasricha TS, Kochar B. Vaping-associated esophagitis. BMC Gastroenterol. 2021;21(1):106. doi: 10.1186/s12876-021-01695-8

[14] Pasricha T.S., Kochar B. Vaping-associated esophagitis // BMC Gastroenterol. 2021. Vol. 21, N. 1. P. 106. doi: 10.1186/s12876-021-01695-8

[15] Yan Z, Xu Y, Li K, Liu L. Genetic correlation between smoking behavior and gastroesophageal reflux disease: insights from integrative multi-omics data. BMC Genomics. 2024;25(1):642. doi: 10.1186/s12864-024-10536-3

[16] Yan Z., Xu Y., Li K., Liu L. Genetic correlation between smoking behavior and gastroesophageal reflux disease: insights from integrative multi-omics data // BMC Genomics. 2024. Vol. 25, N. 1. P. 642. doi: 10.1186/s12864-024-10536-3

[17] Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am. 2015;44(2):203–31. doi: 10.1016/j.gtc.2015.02.001

[18] Runge T.M., Abrams J.A., Shaheen N.J. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma // Gastroenterol Clin North Am. 2015. Vol. 44, N. 2. P. 203–231. doi: 10.1016/j.gtc.2015.02.001

[19] Ivashkin VT, Maev IV, Trukhmanov AS, et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97. doi: 10.22416/1382-4376-2020-30-4-70-97

[20] Ивашкин В.Т., Маев И.В., Трухманов А.С., и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Т. 30, № 4. С. 70–97. doi: 10.22416/1382-4376-2020-30-4-70-97

[21] Ivashkin VT, Maev IV, Trukhmanov AS, Rumyantseva DE. Modern achievements in the diagnosis and treatment of the refractory gastroesophageal reflux disease. Terapevticheskii arkhiv. 2018;90(8):4–12. EDN: XVYHEL doi: 10.26442/terarkh20189084-12

[22] Ивашкин В.Т., Маев И.В., Трухманов А.С., Румянцева Д.Е. Современные достижения в диагностике и лечении рефрактерной формы гастроэзофагеальной рефлюксной болезни // Терапевтический архив. 2018. Т. 90, № 8. С. 4–12. EDN: XVYHEL doi: 10.26442/terarkh20189084-12

[23] Kaybysheva VO, Kucheryavy Yu A, Trukhmanov AS, et al. Results of a multicenter observational study on the use of the international GerdQ questionnaire for the diagnosis of gastroesophageal reflux disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;23(5):15–23. (In Russ.) EDN: RFLZYR

[24] Кайбышева В.О., Кучерявый Ю.А., Трухманов А.С., и др. Результаты многоцентрового наблюдательного исследования по применению международного опросника GerdQ для диагностики гастроэзофагеальной рефлюксной болезни // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013. Т. 23, № 5. С. 15–23. EDN: RFLZYR

[25] Gyawali CP, Yadlapati R, Fass R, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut. 2024;73(2):361–371. doi: 10.1136/gutjnl-2023-330616

[26] Gyawali C.P., Yadlapati R., Fass R., et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0 // Gut. 2024. Vol. 73, N. 2. P. 361–371. doi: 10.1136/gutjnl-2023-330616

[27] Braverman AS, Vegesna AK, Miller LS, et al. Pharmacologic specificity of nicotinic receptor-mediated relaxation of muscarinic receptor precontracted human gastric clasp and sling muscle fibers within the gastroesophageal junction. J Pharmacol Exp Ther. 2011;338(1):37–46. doi: 10.1124/jpet.110.177097

[28] Braverman A.S., Vegesna A.K., Miller L.S., et al. Pharmacologic specificity of nicotinic receptor-mediated relaxation of muscarinic receptor precontracted human gastric clasp and sling muscle fibers within the gastroesophageal junction // J Pharmacol Exp Ther. 2011. Vol. 338, N. 1. P. 37–46. doi: 10.1124/jpet.110.177097

[29] Mori H, Verbeure W, Tanemoto R, et al. Physiological functions and potential clinical applications of motilin. Peptides. 2023;160:170905. doi: 10.1016/j.peptides.2022.170905

[30] Mori H., Verbeure W., Tanemoto R., et al. Physiological functions and potential clinical applications of motilin // Peptides. 2023. Vol. 160. P. 170905. doi: 10.1016/j.peptides.2022.170905

[31] Kuznetsova EI, Rymareva EA, Dicheva DT, Andreev DN. Gastroesophageal reflux disease and diabetes mellitus: pathophysiological mechanisms of comorbidity. Consilium Medicum. 2019;21(8):23–28. doi: 10.26442/20751753.2019.8.190497

[32] Кузнецова Е.И., Рымарева Е.А., Дичева Д.Т., Андреев Д.Н. Гастроэзофагеальная рефлюксная болезнь и сахарный диабет: патофизиологические механизмы коморбидности // Consilium Medicum. 2019. Т. 21, № 8. С. 23–28. doi: 10.26442/20751753.2019.8.190497

[33] Shklyaev AE, Shutova AA, Kazarin DD, et al. Influence of blood motylin concentration on clinical symptomatics of functional dyspepsy. Experimental and Clinical Gastroenterology. 2022;(9):58–64. doi: 10.31146/1682-8658-ecg-205-9-58-64

[34] Шкляев А.Е., Шутова А.А., Казарин Д.Д., и др. Влияние концентрации мотилина в крови на клиническую симптоматику функциональной диспепсии // Экспериментальная и клиническая гастроэнтерология. 2022. № 9. С. 58–64. doi: 10.31146/1682-8658-ecg-205-9-58-64

Funding

Russian National Science FoundationРоссийский научный фонд(23-25-10015)

RIGHTS & PERMISSIONS

Eco-Vector